The COVID-19 pandemic presented a unique challenge for PhRMA, the association representing the country’s biopharmaceutical research companies. Jocelyn Ulrich, Deputy Vice President of Policy, Research and Membership, shared how the industry united around one common goal: beating coronavirus.
“It’s been all hands-on-deck from both members and PhRMA itself,” Jocelyn said.
In addition to developing COVID-19 vaccines and therapeutics, members worked to build vaccine confidence through education and efforts with state and federal stakeholders, including providing grants to community-based organizations. These initiatives from PhRMA to bring more diversity in the biopharmaceutical research ecosystem will make an impact in 2021 and beyond.
– KayAnn P. Schoeneman, Executive Vice President, Curley Company